Loading news...
Canada Post Corp Registered Pension Plan grew its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 110.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 103,344 shares of the biopharmaceutical company's stock after purchasing an additional 54,231 shares during the period. Canada
a16z Perennial Management L.P. bought a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,614 shares of the biopharmaceutical company's stock, valued at approximately $401,000. Other institutional investors and hedge funds
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therap.
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Jones Financial Companies Lllp boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 9.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,803 shares of the biopharmaceutical company's stock after purchasing an additional 7,144 shares during the period. Jones Financial Companies
ABN AMRO Bank N.V. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 46,091 shares of the biopharmaceutical company's stock, valued at approximately $5,138,000. Several other institutional
Machina Capital S.A.S. acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,848 shares of the biopharmaceutical company's stock, valued at approximately $1,648,000. A number of other institutional investors and hedge funds
Ashton Thomas Private Wealth LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 21.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,976 shares of the biopharmaceutical company's stock after buying an additional 10,107 shares during the period. Ashton
AGF Management Ltd. raised its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 81.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,903 shares of the biopharmaceutical company's stock after purchasing an additional 10,303 shares during the period. AGF
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.23, denoting a +2.06% move from the preceding trading day.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.
Atlantic Union Bankshares Corp lowered its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 3.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 176,645 shares of the biopharmaceutical company's stock after selling 7,137 shares during the quarter. Atlantic Union Bankshares Corp's holdings
Convergence Investment Partners LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 23.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,469 shares of the biopharmaceutical company's stock after selling 12,842 shares during the quarter. Gilead Sciences
TD Waterhouse Canada Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 40.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,230 shares of the biopharmaceutical company's stock after selling 10,385 shares during the period. TD Waterhouse
Thrivent Financial for Lutherans boosted its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 20.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 972,988 shares of the biopharmaceutical company's stock after acquiring an additional 165,304 shares during the
Atle Fund Management AB grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 78,169 shares of the biopharmaceutical company's stock after buying an additional 5,004
Y Intercept Hong Kong Ltd purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,131 shares of the biopharmaceutical company's stock, valued at approximately $1,458,000. Several
In the latest trading session, Gilead Sciences (GILD) closed at $141.95, marking a +1.72% move from the previous day.